Lynch syndrome carriers show 4.4% urothelial cancer rate, mostly upper tract
Retrospective · JCO Precis Oncol · 2026-11-14. Number 2 in the UrologyWatch Top 5 for November 14, 2026.
In a registry of 3,274 genetically confirmed Lynch syndrome carriers, 144 (4.4%) developed 224 urothelial carcinomas, over half in the upper urinary tract; MSH2/EPCAM variant carriers had higher risk (HR 4.43) than those with other MMR gene variants.
Why it matters: Raises the question of whether MSH2/EPCAM carriers warrant closer urothelial surveillance than other Lynch syndrome genotypes, pending prospective validation.
Limitation: Retrospective registry analysis dependent on diagnosis coding and incomplete tumor-level molecular data for most cases.
Source: JCO Precis Oncol · PubMed 43024847 · DOI 10.1200/po-26-00227
Loading today's edition…